Back to top
more

SOPHiA GENETICS (SOPH)

(Delayed Data from NSDQ)

$3.53 USD

3.53
46,697

-0.17 (-4.59%)

Updated Nov 15, 2024 03:59 PM ET

After-Market: $3.60 +0.07 (1.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (43 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Standard BioTools (LAB) delivered earnings and revenue surprises of 37.50% and 7.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

What Makes SOPHiA GENETICS (SOPH) a New Buy Stock

by Zacks Equity Research

SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 17.86% and 10.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 148.39% and 3.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 218.75% and 9.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -13.79% and 0.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -10.71% and 4.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -127.94% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 28.57% and 10.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

SOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 35.29% and 3.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -5.88% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q3 Earnings Top Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -1.64% and 2.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?